Abstract
The integrated stress response manifests with the phosphorylation of eukaryotic initiation factor 2α (eIF2α) on serine residue 51 and plays a major role in the adaptation of cells to endoplasmic reticulum stress in the initiation of autophagy and in the ignition of immune responses. Here, we report that lysosomotropic agents, including azithromycin, chloroquine, and hydroxychloroquine, can trigger eIF2α phosphorylation in vitro (in cultured human cells) and, as validated for hydroxychloroquine, in vivo (in mice). Cells bearing a non-phosphorylatable eIF2α mutant (S51A) failed to accumulate autophagic puncta in response to azithromycin, chloroquine, and hydroxychloroquine. Conversely, two inhibitors of eIF2α dephosphorylation, nelfinavir and salubrinal, enhanced the induction of such autophagic puncta. Altogether, these results point to the unexpected capacity of azithromycin, chloroquine, and hydroxychloroquine to elicit the integrated stress response.
Subject terms: Macroautophagy, Viral infection
Introduction
Azithromycin (AZT), chloroquine (CQ), and 3-hydroxychloroquine (HCQ) have attracted much attention over the past months as possible (and controversial) therapeutic agents for the treatment of coronavirus disease-19 (COVID-19)1,2. At this point, it has not been resolved whether the frequently administered combination regimen of AZT and HCQ (often supplemented with zinc) itself reduces the morbidity and mortality of COVID-19 or whether accompanying measures (such as provision of anti-diabetic, anti-hypertensive, anti-inflammatory, and/or anti-thrombotic agents) or even placebo effects account for the clinical efficiency of AZT + HCQ, which are more frequently observed in retrospective analyses and uncontrolled clinical studies3–5 than in prospective randomized studies6–9.
AZT is a macrolide antibiotic, while CQ and HCQ are antimalarial drugs. HCQ is also been widely used for the treatment of rheumatoid arthritis and systemic lupus erythematosus10,11. All the three agents are lysosomotropic12–14, meaning that they are sufficiently lipophilic to penetrate into cells but also weak bases so that they get protonated at low pH to become trapped in lysosomes, hence gradually increasing their concentration in the lysosomal lumen until they destabilize lysosomal membranes due to detergent-like effects, causing a loss of lysosomal acidification and blockade of lysosomal functions15,16 that ultimately activates homeostatic circuitries including the activation of transcription factors such as TFEB and TFE3 for lysosomal biogenesis17. In addition, the loss of lysosomal acidity/function observed in cells treated with AZT, CQ, or HCQ results in the blockade of lysosomal fusion with autophagosomes, thus stalling autophagic flux and causing the accumulation of autophagosomes that cannot be eliminated18–20. Moreover, CQ and HCQ can stimulate lysosomal membrane permeabilization that secondarily elicits the mitochondrial pathway of apoptosis21, hence resulting in cell death, likely contributing to the toxicity of these agents22,23.
The integrated stress response (ISR) consists in the phosphorylation of the phylogenetically conserved eukaryotic initiation factor 2α (eIF2α) by a series of eIF2α kinases (EIF2K1 to 4) and plays a cardinal role in the adaptation of stress to endoplasmic reticulum (ER) stress (in particular, the accumulation of unfolded or misfolded proteins in the ER lumen)24, in the innate cellular defense against viral infections (to block the translation of virus-encoded RNAs into protein)25–27, as well as in the initiation of autophagy (which also can lead to the elimination of intracellular pathogens)28–31. Moreover, eIF2α phosphorylation contributes to the phenomenon of “immunogenic cell death” (ICD)32–34, which likely plays a major role in connecting the virus-induced death of infected cells to immune response that ultimately lead to the active elimination of virus-infected cells by cytotoxic T lymphocytes35–37. This latter effect is achieved due to the contribution of eIF2α phosphorylation to (i) autophagy, which enables the lysosomal secretion of ATP (which is a major chemoattractant for dendritic cell precursors)28,29,31,38 and (ii) the exposure of the ER lumen protein calreticulin at the cell surface (where it acts as an eat-me signal to render dying/dead cells palatable to dendritic cells, allowing them to present viral antigens to T lymphocytes)33,39–41.
In view of the considerable (patho)physiological relevance of ISR, we decided to investigate whether AZT, CQ, or HCQ may induce this phenomenon. Here, we show that these three agents induce signs of ISR in vivo, and that ISR contributes to the accumulation of stalled autophagosomes as well as to the cytotoxicity of these agents.
Results
Lysosomotropic agents induce eIF2a phosphorylation in vitro
Human U2OS osteosarcoma cells stably expressing a GFP-LC3 fusion protein exhibit GFP-LC3 dots in the cytoplasm (corresponding to “autophagic puncta”)42 in response to the autophagy inducer torin1 (TOR, an inhibitor of mechanistic target of rapamycin, mTOR) and the lysosomal inhibitor bafilomycin A1 (BafA1, an inhibitor of the vacuolar-type H+-ATPase (V-ATPase) that is required for lysosomal acidification)43. Similar to BafA1, the three lysosomotropic agents AZT, CQ, and HCQ did not cause any cytotoxicity in the timeframe of the experiment (Fig. 1A–D) but stimulated a dose-dependent increase in GFP-LC3 dots. The formation of GFP-LC3 puncta was observed in wild-type U2OS and human glioma H4 cells but not in cells that are deficient for the essential autophagy protein ATG5 and which acts upstream of LC3 to facilitate lipidation and membrane association (Fig. 1E, F and Supplementary Fig. 1). Moreover, AZT, CQ, and HCQ stimulated the translocation of the transcription factors TFEB and TFE3 from the cytoplasm to the nuclei, as determined in U2OS cells expressing a GFP-TFEB fusion protein (Fig. 1G, H) or by immunofluorescence detection of TFE3 (Fig. 1I, J). AZT, CQ, and HCQ inhibited autophagic flux in U2OS RFP-GFP-LC3 tandem reporter cells, as can be expected from agents that perturb lysosomal function (Supplementary Fig. 2)15,16,44. In addition, AZT, CQ, and HCQ induced the phosphorylation of eIF2α (as measured by immunofluorescence and immunoblot using a phosphoneoepitope-specific antibody) (Fig. 2A, B and Supplementary Fig. 3)45, the activation of the transcription factor CHOP (as indicated by the expression of GFP placed under the control of the CHOP promoter) (Fig. 2C, D), the upregulation of ATF6 (as indicated by the expression of an ATF6-GFP fusion protein) (Fig. 2E, F), and the activation of XBP1 (as indicated by the expression of an XBP1-GFP/Venus fusion protein in which GFP/Venus is only expressed after that IRE1α has caused the splicing of the corresponding mRNA (Fig. 2G, H). However, in quantitative terms, the effects of AZT, CQ, and HCQ on CHOP, ATF6, and XBP1 appear relatively minor when compared to the positive controls thapsigargin and tunicamycin employed to elicit ER stress (Fig. 2C–H). Only the level of eIF2α phosphorylation induced by AZT, CQ, and HCQ reaches that of the positive controls (Fig. 2A, B). Similarly, CQ and HCQ (but not AZT) induced a relatively low level of NF-kB activation as compared to the positive control, tumor necrosis factor-α (Supplementary Fig. 4). We conclude that AZT, CQ, and HCQ are potent perturbators of lysosomal function as well as potent inducers of the ISR consisting in eIF2α phosphorylation.
eIF2a phosphorylation is required for the induction of autophagic puncta
TFEB and TFE3 are well known pro-autophagic transcription factors46,47. Accordingly, their double knockout (DKO) attenuated the induction of GFP-LC3 puncta by AZT, CQ, and HCQ (Fig. 3A, B). Many autophagy inducers require eIF2α phosphorylation as a mandatory step for the ignition of the process48. Accordingly, we observed that a knockin mutation that renders eIF2α non-phosphorylatable (due to the replacement of serine in position 51 by an alanine residue: genotype eIF2αS51A/S51A) strongly inhibited the induction of GFP-LC3 puncta by AZT, CQ, and HCQ (Fig. 3C, D). Similarly, inhibition of ER stress with the chemical chaperone 4-phenylbutyric acid (4-PBA)49 attenuated the induction of GFP-LC3 puncta by AZT, CQ, and HCQ (Fig. 4A, B). Conversely, treatment of the cells with two inhibitors of eIF2α dephosphorylation, nelfinavir50 and salubrinal51, enhanced the formation of GFP-LC3 puncta in response to AZT, CQ, and HCQ (Fig. 4A, B and Supplementary Fig. 5).
In accord with previous work21, CQ and HCQ induces some degree of cellular toxicity, leading to the manifestation of apoptotic and necrotic events that can be distinguished by dual staining with annexin-V-FITC (which stains apoptotic and necrotic cells) the vital dye 4′,6-diamidino-2-phenylindole (DAPI, which only stains necrotic cells)52. Among the genotypes evaluated in this paper (ATG5−/−, eIF2αS51A/S51A, TFEB−/−, TFE3−/−, TFEB/TFE3 DKO, PERK−/−) the eIF2αS51A knockin mutation rendering eIF2α non-phosphorylatable had the strongest effect on apoptosis induction by CQ and HCQ (Fig. 5A), increasing cellular killing by CQ and HCQ but not by the general tyrosine kinase inhibitor and apoptosis inducer staurosporin (STS) (Fig. 5B and Supplementary Fig. 6). These results point to the ISR as central for the effects of CQ and HCQ.
Lysosomotropic agents induce eIF2α phosphorylation in vivo
The aforementioned results have been obtained in vitro, calling for their in vivo validation. For this, we injected mice intraperitoneally with HCQ (at a dose that inhibits autophagic flux)53–56 alone or in combination with AZT (supplemented in the drinking water). Of note, HCQ (but less so AZT) induced a remarkable and significant increase in eIF2α phosphorylation that was detectable by immunoblot in liver extracts (Fig. 6A, B) but less so in the myocardium (Supplementary Fig 7). In addition, one single injection of HCQ was able to stimulate a significant increase in eIF2α phosphorylation in several circulating leukocyte subsets (in particular neutrophil granulocytes, lymphocytes, and monocytes), as determined by immunofluorescence staining and imaging flow cytometry (Fig. 6D, E). Thus, HCQ can induce eIF2α phosphorylation in vivo, supporting the capacity of this agent to activate ISR.
Discussion
As we show in this work, lysosomotropic agents including AZR, CQ, and HCQ are capable of stimulating the ISR. The capacity of these agents to induce the cardinal hallmark of ISR, eIF2α phosphorylation, is observed at similar concentrations as those required to induce the accumulation of autophagic puncta and to activate the transcription factors TFEB and TFE3 in a dose of 10–40 µM. The accumulation of autophagic puncta induced by AZT, CQ, and HCQ requires the initial steps of autophagy, as illustrated by the fact that ATG5-deficient cells fail to demonstrate this phenomenon. This is in accordance with findings showing that CQ can induce non-canonical V-ATPase-dependent LC3 lipidation57. Moreover, AZT, CQ, and HCQ were unable to elicit the accumulation of LC3-binding autophagosomes in cells expressing a non-phosphorylatable mutant of eIF2α, suggesting causality between ISR and the observed phenomenon. This conjecture was further supported by the observation that two inhibitors of the dephosphorylation of eIF2α enhanced autophagosome accumulation in vitro. Moreover, the apoptosis-inducing effect of CQ and HCQ was reduced in cells bearing mutant eIF2α.
The ISR plays a major role in the inhibition of viral replication. Indeed, multiple viruses have developed strategies to subvert the ISR, either by directly inhibiting eIF2α kinases or by deploying a decoy that resembles eIF2α, hence preventing the phosphorylation of the cellular protein25,58,59. In addition, a protein encoded by coronavirus counteracts the ISR at its very core by acting as a competitive inhibitor of the phospho-eIF2α-eIF2β interaction27. Hence, the question comes up whether the reported in vitro antiviral effects of CQ and HCQ27,60 are linked to their capacity to elicit the ISR, thus augmenting an innate immune response (such as the initiation of a type-1 interferon response61,62, beyond their action on acidophilic cellular compartments63–65.
The ISR also has a fundamental role in ICD. In a plausible scenario, cells infected by viruses ultimately succumb to viral infection. If the virus (or other agents) induce the ISR, cell death would be perceived as immunogenic, hence favoring the stimulation of an immune response that involves dendritic cells as antigen presenters that then “educate” cytotoxic T lymphocytes to recognize MHC class I-restricted viral peptides expressed on the surface of infected cells37,66. By clearing infected cells, the immune system then can remove all virus-replicative niches from the body to subsequently establish a memory response that protects the patient from challenges by the same or antigenically similar viruses.
We have found in the past that artificial induction of the ISR by agents that stimulate an ER stress response (such as thapsigargin injected into tumors) or inhibit the dephosphorylation of eIF2α (such as salubrinal and a peptides inhibiting the phosphatase PP1 interacting with its cofactor GADD34) can vigorously stimulate anticancer immune responses linked to ICD67–70. In this context, it is noteworthy that agents that selectively stimulate ISR but not any other manifestation of the unfolded stress response (such as the activation of ATF6 and that of IRE1/XBP1) are more efficient ICD inducers than agents with a broad effect on several arms of the unfolded stress response33,71,72. In quantitative terms, when compared to appropriate positive controls (thapsigargin, tunicamycin), AZT, CQ, and HCQ induced a strong ISR but scarce ATF6 and IRE1/XBP1 activation. Hence, these lysosomotropic agents induce a pattern of response that would be compatible with a pro-ICD action. However, further virological and immunological experimentation will be required to (in)validate this conjecture.
In essence, our results demonstrate that AZT, CQ, and HCQ stimulate the ISR. This might contribute to the potential antiviral and immunostimulatory effects of such lysosomotropic agents. However, to definitively prove the mechanistic relevance of such effects, it would be necessary to develop small animal models73 in which AZT, CQ, and HCQ, alone or in combination would have significant and reproducible antiviral activity.
Materials and methods
Cell culture and chemicals
Culture media and supplements for cell culture were purchased from Gibco-Life Technologies (Carlsbad, CA, USA) and plastic ware came from Greiner Bio-One (Kremsmünster, Austria) and Corning (Corning, NY, USA). Wild-type human osteosarcoma U2OS or human glioma H4 cells were purchased from the American Type Culture Collection (ATCC, Rockefeller, MD, USA), their derivatives stably expressing GFP-LC3, RFP-LC3, or RFP-GFP-LC3 were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 10 U mL−1 penicillin sodium, and 10 μg mL−1 streptomycin sulfate at 37 °C in a humidified atmosphere with 5% CO2. TFEB-deficient (TFEB−/−), TFE3-deficient (TFE3−/−), TFEB and TFE3-double deficient (TF DKO), ATG5-deficient (ATG5−/−), and PERK-deficient (PERK−/−) U2OS cells were generated by means of CRISPR/Cas9-mediated genome editing, as per the manufacturer’s recommendations31,74. U2OS cells stably expressing RFP-LC3 bearing a non-phosphorylatable mutant of eIF2α (eIF2αS51A) were constructed by means of CRISPR/Cas9 knockin as previously detailed31. In addition, U2OS cells stably expressing GFP-TFEB, a GFP under the DDIT3 promoter (CHOP::GFP), GFP-ATF6, and XBP1s-ΔDBD-venus were generated by our group in the past33,74. Chloroquine diphosphate salt (CQ, #C6628), hydroxychloroquine sulfate (HCQ, #PHR1782), azithromycin (AZT, #75199), 4-phenylbutyric acid (4-PBA, #P21005), nelfinavir (NFV, #CDS021783), salubrinal (SAL, #324895), thapsigargin (TG, #T9033), tunicamycin (TM, #T7765), bafilomycin A1 (BafA1, #B1793), tumor necrosis factor-α (TNF-α, #T6674), torin1 (TOR, #475991), and staurosporine (STS, #S4400) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
High-content microscopy
Human osteosarcoma U2OS-GFP-LC3 wild type or TFEB and TFE3-double deficient (TF DKO), ATG5 deficient (ATG5−/−), RFP-GFP-LC3, RFP-LC3 wild type or mutant cells expressing a non-phosphorylatable knockin of eIF2α (eIF2αS51A/S51A) were seeded in 384-well µclear imaging plates (Greiner Bio-One) at a density of 2 × 103 cells per well and allowed to adapt for overnight. Furthermore, ATG5−/−, eIF2αS51A/S51A, and TF DKO cells were treated for 6 h. Moreover, 2 × 103 U2OS cells either wild type or stably expressing GFP-ATF6, CHOP::GFP, GFP-TFEB, or XBP1-ΔDBD-venus were seeded in 384-well black imaging plates (Greiner Bio-One) and let adhere overnight. Cells were then treated for 6 h to assess TFEB translocation, and 24 h to monitor abundance of ATF6 and spliced XBP1 (XBP1s), or to measure CHOP expression. Next, cells were fixed with 3.7% formaldehyde (#F8775; Sigma-Aldrich) supplemented with 1 μg/ml Hoechst 33342 (#H3570; Thermo Fisher Scientific) at 4 °C overnight. After washing the cells, the plates were sealed and analyzed by automated microscopy. Image acquisition was performed using an ImageXpress Micro XL automated microscope (Molecular Devices, Sunnyvale, CA, US) equipped with a ×20 PlanApo objective (Nikon, Tokyo, Japan), followed by automated image segmentation. A minimum of four images were acquired per well, and experiments involved at least triplicate assessments.
Image segmentation and data analysis
Upon acquisition, images were segmented and analyzed using R. Briefly, cells were segmented and divided into nuclear and cytoplasmic regions based on the nuclear Hoechst staining and cytoplasmic GFP or RFP signal. After exclusion of cellular debris and dead cells, parameters of interest were normalized, statistically evaluated, and graphically depicted with R software. Using R, images were extracted and pixel intensities scaled to be visible (in the same extent for all images of a given experiment).
Immunofluorescence
Cells were treated for 16 h to detect eIF2α phosphorylation (PeIF2α) and TFE3 expression, or 6 h to measure p65 nuclear translocation. Then cells were fixed with 3.7% PFA at 4 °C overnight. For the immunostaining of TFE3, p65, and phospho-eIF2α (Ser51), fixed cells were permeabilized with 0.1% Triton X-100 (#X100; Sigma-Aldrich) on ice, and unspecific antibody binding was blocked with 5% bovine serum albumin (BSA, w/v in PBS) for 1 h. Then cells were incubated with antibodies specific to TFE3 (#ab93808, 1:200; Abcam), phospho-eIF2 alpha (Ser51) (#ab32157, 1:1000; Abcam), or p65 (#4764, 1:100; Cell Signalling Technology) at 4 °C overnight. After washing with PBS twice, AlexaFluor 568-conjugated secondary antibodies (Thermo Fisher Scientific) were employed for additional 2 h at RT. Then cells were washed and imaged by automated fluorescence microscopy as described above. The nuclear-to-cytoplasm intensity ratio of TFE3 and p65 as well as the cytoplasmic intensity of phospho-eIF2α (Ser51) were measured and normalized to controls.
Imaging cytofluorometric analysis
Six hundred microliters of total blood were diluted in 25 mL red blood cell lysis buffer (BioLegend) and incubated for 10 min at room temperature. Then the cells were washed twice in PBS, fixed with 4% PFA for 20 min at room temperature, permeabilized with 0.25% Tween-20 for 15 min at 4 °C, and blocked with 2% BSA in PBS. Cells were incubated with anti-phospho-eIF2 alpha (Ser51) and AlexaFluor 647-conjugated anti-mouse PTPRC/CD45 antibody (#clone 30-F11; BioLegend) for 1 h at room temperature. Then cells were incubated for 1 h with donkey AlexaFluor488-conjugated secondary antibody and Hoechst 33342 (0.5 µg/µL). Multispectral imaging flow cytometry was performed on an AMNIS ImageStream X Mark II equipped with 375-, 488-, 561-, and 642 nm lasers using the ×60 magnification lens. At least 6000 cells/sample were acquired for each sample. The analysis was performed with IDEAS software v6.2. Exclusively focused images were included in the analysis. Selection was based on the gradient RMS feature of bright field images. A compensation matrix was calculated using single color fluorescent controls. This matrix was applied to each file and singlets were then gated on aspect ratio vs. area of bright field and leukocyte subpopulations were gated on a pictogram indicating the intensity of PTPRC/CD45 staining vs. dark field. Following the intensity of peIF2α was quantified in each cell.
Quantification of cell death by flow cytometry
Cell death was assessed by means of the Alexa Fluor 647 Annexin V (#640943; BioLegend) and DAPI (#62248; Thermo Fisher Scientific) kit following the manufacturer’s instructions. Briefly, cells were seeded in 12-well plates (with 5 × 104 cells per well) and incubated at 37 °C in a humidified atmosphere with 5% CO2 for 24 h, then cells were collected and washed in PBS containing 0.5% BSA before the cell pellet was resuspended in 100 µL of Annexin V Binding Buffer (#422201, BioLegend) containing Alexa Fluor 647-coupled Annexin V. Samples were then incubated at room temperature in the dark for 15 min before adding 100 µL of PBS containing 0.5% BSA and 2 µg/mL DAPI solution. Acquisitions were performed on a BD LSRFortessa™ cell analyzer (BD Biosciences, San Jose, California, USA), and data were statistically analyzed using the FlowJo 10.5.3 software (Tree Star, Ashland, Oregon, USA).
In vivo experimentation
The animal experiment was approved by the Gustave Roussy ethics committee with the project number: 24771–2020032413235413, and all procedures were performed in compliance with the governmental and institutional guidelines and regulations. Mice were kept in a temperature-controlled SPF environment (12 h light/dark cycles) with food and water ad libitum. Eight-week-old female C57Bl/6j mice were obtained from ENVIGO (France). To quantify the in vivo phosphorylation eIF2α (S51), naive mice were intraperitoneally (i.p.) treated with HCQ at a dose of 50 mg/kg/day in 200 µL PBS daily for 10 days75,76; fed with AZT in autoclaved drinking water at a concentration of 3 mg/L (purchased from the local pharmacy) for 5 days, and the solution was changed daily throughout the treatment period77,78. All mice were sacrificed at day 10, 4 h post-injection with HCQ, and livers and hearts were snap frozen in liquid nitrogen.
Immunoblotting
Thirty milligrams of liver tissue were dissociated in Precellys lysing tubes (#CK28; Bertin Technologies SAS, France) containing 1 mL of RIPA lysis buffer (#89901; Invitrogen) by using the Precellys 24 homogenizer (Bertin Technologies SAS) at 6500 r.p.m. for 60 s, followed by spinning at 14 s 103 d g for 15 min to collect the supernatant that contains soluble proteins. Protein concentration was measured by means of by the BCA Assay (Bio-Rad, Hercules, CA, USA). The protein solution was mixed with 4× loading buffer (#NP0008; Invitrogen), and denatured at 100 °C for 10 min before subjected to western blotting. Forty micrograms of total protein were resolved on 4–12% NuPAGE Bis-Tris protein gels (#NP0336BOX; Invitrogen) and transferred to PVDF membranes (#IPFL00010; Merck Millipore). The membranes were blocked with 5% non-fat dry milk in TBST for 1 h before incubating with primary antibodies to phospho-eIF2 alpha (Ser51) (#ab32157, 1:1000; Abcam) overnight at 4 °C. Membranes were washed several times with TBST for 10 min each before incubation with HRP-conjugated secondary antibody (#4050-05; SouthernBiotech) for 2 h at room temperature. At last, the membranes were washed again and subjected to chemiluminescence detection with the Amersham ECL Prime detection reagent kit (#RPN2236; GE Healthcare) on an ImageQuant LAS 4000 software-assisted imager. The exposed membranes were stripped and re-probed with antibodies specific to β-actin (#ab20727; Abcam) as loading control using the procedure described above. Densitometry was performed using the ImageQuant TL software (GE Healthcare, Piscataway, NJ, USA).
Image and data processing
Images were segmented using the EBImage package (available from Bioconductor repository https://www.bioconductor.org) with the R software. The nuclear region was defined using a polygon mask based on the nuclear Hoechst signal, and a second polygon mask was generated using the cytoplasmic GFP or RFP signal. For the assessment of autophagic vesicles, a third mask was created on cytoplasmic regions exhibiting a high intensity signal of GFP or RFP corresponding with LC3 aggregates.
Following image segmentation, the data were extracted and reduced using the R software. After exclusion of cellular debris and dead cells, parameters of interest were normalized to controls, statistically evaluated, and graphically depicted with R software. Using R, images were extracted and pixel intensities scaled to be visible (to the same extent for all images of a given experiment).
Statistical analysis
Unless otherwise mentioned, data are reported as means ± SD of triplicate determinations and experiments were repeated at least three times yielding similar results, and statistical significance was assessed by Student’s t-test with a P value adjustment based on the Benjamini–Hochberg procedure.
Supplementary information
Acknowledgements
This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001. A.-L.T. and Q.W. are supported by a CSC fellowship. G.K. is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR)—Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Ruban Rose”; Cancéropôle Ile-de-France; Chancelerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China (GDW20171100085), Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology (ANR-18-IDEX-0001); the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM).
Author contributions
Concept and design: O.K. and G.K. Writing, review, and/or revision of the manuscript: O.K., M.L., and G.K. Experimentation and analysis: A.-L.T., Q.W., P.L., L.Z., I.M., and M.L. All authors approve the final version of the article.
Conflict of interest
G.K. and O.K. are cofounders of Samsara Therapeutics, a biotech company developing autophagy inducers for the treatment of aging. The other authors have no relevant conflict of interest to declare.
Ethics approval
The animal experiment was approved by the Gustave Roussy ethics committee with the project number: 24771-2020032413235413, and all procedures were performed in compliance with the governmental and institutional guidelines and regulations.
Footnotes
Edited by G. Melino
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Ai-Ling Tian, Qi Wu, Marion Leduc
Contributor Information
Oliver Kepp, Email: captain.olsen@gmail.com.
Guido Kroemer, Email: kroemer@orange.fr.
Supplementary information
Supplementary Information accompanies this paper at (10.1038/s41419-020-03324-w).
References
- 1.Gautret P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents. 2020;56:105949. doi: 10.1016/j.ijantimicag.2020.105949. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Holopigian K, Snow J, Seiple W, Siegel I. Variability of the pattern electroretinogram. Doc. Ohthalmol. 1988;70:103–115. doi: 10.1007/BF00154741. [DOI] [PubMed] [Google Scholar]
- 3.Gautret P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med. Infect. Dis. 2020;34:101663. doi: 10.1016/j.tmaid.2020.101663. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Lagier, J. C. et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. Travel Med. Infect. Dis. 101791, 10.1016/j.tmaid.2020.101791 (2020). [DOI] [PMC free article] [PubMed]
- 5.Mikami, T. et al. Risk factors for mortality in patients with COVID-19 in New York City. J. Gen. Intern. Med.10.1007/s11606-020-05983-z (2020). [DOI] [PMC free article] [PubMed]
- 6.Tang W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. doi: 10.1136/bmj.m1849. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Boulware, D. R. et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N. Engl. J. Med.10.1056/NEJMoa2016638 (2020). [DOI] [PMC free article] [PubMed]
- 8.Das S, Bhowmick S, Tiwari S, Sen S. An updated systematic review of the therapeutic role of hydroxychloroquine in coronavirus disease-19 (COVID-19) Clin. Drug Investig. 2020;40:591–601. doi: 10.1007/s40261-020-00927-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Liu W, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. CMAJ. 2020;192:E734–E744. doi: 10.1503/cmaj.200647. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23:231–269. doi: 10.1007/s10787-015-0239-y. [DOI] [PubMed] [Google Scholar]
- 11.Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol. 2020;16:155–166. doi: 10.1038/s41584-020-0372-x. [DOI] [PubMed] [Google Scholar]
- 12.Weissmann G. Labilization and stabilization of lysosomes. Fed. Proc. 1964;23:1038–1044. [PubMed] [Google Scholar]
- 13.Ignarro LJ. Effects of anti-inflammatory drugs on the stability of rat liver lysosomes in vitro. Biochem. Pharmacol. 1971;20:2847–2860. doi: 10.1016/0006-2952(71)90196-1. [DOI] [PubMed] [Google Scholar]
- 14.Carevic O, Djokic S. Comparative studies on the effects of erythromycin A and azithromycin upon extracellular release of lysosomal enzymes in inflammatory processes. Agents Actions. 1988;25:124–131. doi: 10.1007/BF01969103. [DOI] [PubMed] [Google Scholar]
- 15.Kuzu OF, Toprak M, Noory MA, Robertson GP. Effect of lysosomotropic molecules on cellular homeostasis. Pharmacol. Res. 2017;117:177–184. doi: 10.1016/j.phrs.2016.12.021. [DOI] [PubMed] [Google Scholar]
- 16.Pisonero-Vaquero S, Medina DL. Lysosomotropic drugs: pharmacological tools to study lysosomal function. Curr. Drug Metab. 2017;18:1147–1158. doi: 10.2174/1389200218666170925125940. [DOI] [PubMed] [Google Scholar]
- 17.Ploper D, De Robertis EM. The MITF family of transcription factors: role in endolysosomal biogenesis, Wnt signaling, and oncogenesis. Pharmacol. Res. 2015;99:36–43. doi: 10.1016/j.phrs.2015.04.006. [DOI] [PubMed] [Google Scholar]
- 18.Wisner-Gebhart AM, Brabec RK, Gray RH. Morphometric studies of chloroquine-induced changes in hepatocytic organelles in the rat. Exp. Mol. Pathol. 1980;33:144–152. doi: 10.1016/0014-4800(80)90015-5. [DOI] [PubMed] [Google Scholar]
- 19.Boya P, et al. Inhibition of macroautophagy triggers apoptosis. Mol. Cell. Biol. 2005;25:1025–1040. doi: 10.1128/MCB.25.3.1025-1040.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Renna M, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J. Clin. Investig. 2011;121:3554–3563. doi: 10.1172/JCI46095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Boya P, et al. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene. 2003;22:3927–3936. doi: 10.1038/sj.onc.1206622. [DOI] [PubMed] [Google Scholar]
- 22.Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and hydroxychloroquine for cancer therapy. Mol. Cell. Oncol. 2014;1:e29911. doi: 10.4161/mco.29911. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Kroemer G, Galluzzi L. Lysosome-targeting agents in cancer therapy. Oncotarget. 2017;8:112168–112169. doi: 10.18632/oncotarget.21451. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat. Rev. Mol. Cell Biol. 2020;21:421–438. doi: 10.1038/s41580-020-0250-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Kepp O, et al. Viral subversion of immunogenic cell death. Cell Cycle. 2009;8:860–869. doi: 10.4161/cc.8.6.7939. [DOI] [PubMed] [Google Scholar]
- 26.Johnston, B. P. & McCormick, C. Herpesviruses and the unfolded protein response. viruses12, 10.3390/v12010017 (2019). [DOI] [PMC free article] [PubMed]
- 27.Rabouw, H. H. et al. Inhibition of the integrated stress response by viral proteins that block p-eIF2-eIF2B association. Nat. Microbiol.10.1038/s41564-020-0759-0 (2020). [DOI] [PubMed]
- 28.Talloczy Z, et al. Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway. Proc. Natl Acad. Sci. USA. 2002;99:190–195. doi: 10.1073/pnas.012485299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol. Cell. 2010;40:280–293. doi: 10.1016/j.molcel.2010.09.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Costa-Mattioli, M. & Walter, P. The integrated stress response: from mechanism to disease. Science368, 10.1126/science.aat5314 (2020). [DOI] [PMC free article] [PubMed]
- 31.Humeau J, et al. Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) in autophagy. Cell Death Dis. 2020;11:433. doi: 10.1038/s41419-020-2642-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Kepp O, et al. eIF2alpha phosphorylation as a biomarker of immunogenic cell death. Semin. Cancer Biol. 2015;33:86–92. doi: 10.1016/j.semcancer.2015.02.004. [DOI] [PubMed] [Google Scholar]
- 33.Bezu L, et al. eIF2alpha phosphorylation is pathognomonic for immunogenic cell death. Cell Death Differ. 2018;25:1375–1393. doi: 10.1038/s41418-017-0044-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Humeau J, et al. Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. EMBO Mol. Med. 2020;12:e11622. doi: 10.15252/emmm.201911622. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Uhl M, et al. Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells. Cell Death Differ. 2009;16:991–1005. doi: 10.1038/cdd.2009.8. [DOI] [PubMed] [Google Scholar]
- 36.Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Reply: the complement system is also important in immunogenic cell death. Nat. Rev. Immunol. 2017;17:143. doi: 10.1038/nri.2016.143. [DOI] [PubMed] [Google Scholar]
- 37.Tappe KA, et al. Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8(+) T cell proliferation. Eur. J. Immunol. 2018;48:2042–2054. doi: 10.1002/eji.201847632. [DOI] [PubMed] [Google Scholar]
- 38.Martins I, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ. 2014;21:79–91. doi: 10.1038/cdd.2013.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Madeo F, et al. Phylogenetic conservation of the preapoptotic calreticulin exposure pathway from yeast to mammals. Cell Cycle. 2009;8:639–642. doi: 10.4161/cc.8.4.7794. [DOI] [PubMed] [Google Scholar]
- 40.Senovilla L, Demont Y, Humeau J, Bloy N, Kroemer G. Image cytofluorometry for the quantification of ploidy and endoplasmic reticulum stress in cancer cells. Methods Mol. Biol. 2017;1524:53–64. doi: 10.1007/978-1-4939-6603-5_3. [DOI] [PubMed] [Google Scholar]
- 41.Giglio P, et al. PKR and GCN2 stress kinases promote an ER stress-independent eIF2alpha phosphorylation responsible for calreticulin exposure in melanoma cells. Oncoimmunology. 2018;7:e1466765. doi: 10.1080/2162402X.2018.1466765. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Bravo-San Pedro JM, et al. High-throughput quantification of GFP-LC3(+) dots by automated fluorescence microscopy. Methods Enzymol. 2017;587:71–86. doi: 10.1016/bs.mie.2016.10.022. [DOI] [PubMed] [Google Scholar]
- 43.Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Autophagy. 2016;12:1–222. doi: 10.1080/15548627.2015.1100356. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Perera RM, Di Malta C, Ballabio A. MiT/TFE family of transcription factors, lysosomes, and cancer. Annu. Rev. Cancer Biol. 2019;3:203–222. doi: 10.1146/annurev-cancerbio-030518-055835. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Bezu L, Wu Chuang A, Humeau J, Kroemer G, Kepp O. Quantification of eIF2alpha phosphorylation during immunogenic cell death. Methods Enzymol. 2019;629:53–69. doi: 10.1016/bs.mie.2019.04.010. [DOI] [PubMed] [Google Scholar]
- 46.Saftig P, Haas A. Turn up the lysosome. Nat. Cell Biol. 2016;18:1025–1027. doi: 10.1038/ncb3409. [DOI] [PubMed] [Google Scholar]
- 47.Di Malta C, Cinque L, Settembre C. Transcriptional regulation of autophagy: mechanisms and diseases. Front. Cell Dev. Biol. 2019;7:114. doi: 10.3389/fcell.2019.00114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Acevo-Rodriguez PS, Maldonado G, Castro-Obregon S, Hernandez G. Autophagy regulation by the translation machinery and its implications in cancer. Front. Oncol. 2020;10:322. doi: 10.3389/fonc.2020.00322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Kolb PS, et al. The therapeutic effects of 4-phenylbutyric acid in maintaining proteostasis. Int. J. Biochem. Cell Biol. 2015;61:45–52. doi: 10.1016/j.biocel.2015.01.015. [DOI] [PubMed] [Google Scholar]
- 50.De Gassart A, et al. An inhibitor of HIV-1 protease modulates constitutive eIF2alpha dephosphorylation to trigger a specific integrated stress response. Proc. Natl Acad. Sci. USA. 2016;113:E117–E126. doi: 10.1073/pnas.1514076113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Boyce M, et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science. 2005;307:935–939. doi: 10.1126/science.1101902. [DOI] [PubMed] [Google Scholar]
- 52.Pozarowski, P., Grabarek, J. & Darzynkiewicz, Z. Current Protocols in Cell BiologyChapter 18, 18.8.1–18.8.33 (John Wiley & Sons, Inc., 2004). [DOI] [PubMed]
- 53.Ruiz A, et al. Effect of hydroxychloroquine and characterization of autophagy in a mouse model of endometriosis. Cell Death Dis. 2016;7:e2059. doi: 10.1038/cddis.2015.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Burikhanov R, et al. Chloroquine-inducible Par-4 secretion is essential for tumor cell apoptosis and inhibition of metastasis. Cell Rep. 2017;18:508–519. doi: 10.1016/j.celrep.2016.12.051. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Collins KP, Jackson KM, Gustafson DL. Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J. Pharmacol. Exp. Therap. 2018;365:447–459. doi: 10.1124/jpet.117.245639. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Qiao X, et al. Hydroxychloroquine Improves obesity-associated insulin resistance and hepatic steatosis by regulating lipid metabolism. Front. Pharmacol. 2019;10:855. doi: 10.3389/fphar.2019.00855. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Florey O, Gammoh N, Kim SE, Jiang X, Overholtzer M. V-ATPase and osmotic imbalances activate endolysosomal LC3 lipidation. Autophagy. 2015;11:88–99. doi: 10.4161/15548627.2014.984277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Jheng JR, Ho JY, Horng JT. ER stress, autophagy, and RNA viruses. Front. Microbiol. 2014;5:388. doi: 10.3389/fmicb.2014.00388. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Liu Y, et al. The role of host eIF2alpha in viral infection. Virol. J. 2020;17:112. doi: 10.1186/s12985-020-01362-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Andreani J, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb. Pathog. 2020;145:104228. doi: 10.1016/j.micpath.2020.104228. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Balachandran S, et al. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity. 2000;13:129–141. doi: 10.1016/S1074-7613(00)00014-5. [DOI] [PubMed] [Google Scholar]
- 62.Liang Q, Deng H, Sun CW, Townes TM, Zhu F. Negative regulation of IRF7 activation by activating transcription factor 4 suggests a cross-regulation between the IFN responses and the cellular integrated stress responses. J. Immunol. 2011;186:1001–1010. doi: 10.4049/jimmunol.1002240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Carmona-Gutierrez D, et al. Digesting the crisis: autophagy and coronaviruses. Microb. Cell. 2020;7:119–128. doi: 10.15698/mic2020.05.715. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Bonam, S. R., Muller, S., Bayry, J. & Klionsky, D. J. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. Autophagy10.1080/15548627.2020.1779467 (2020). [DOI] [PMC free article] [PubMed]
- 65.Bello-Perez, M., Sola, I., Novoa, B., Klionsky, D. J. & Falco, A. Canonical and noncanonical autophagy as potential targets for COVID-19. Cells10.3390/cells9071619 (2020). [DOI] [PMC free article] [PubMed]
- 66.Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 2017;17:97–111. doi: 10.1038/nri.2016.107. [DOI] [PubMed] [Google Scholar]
- 67.Obeid M, et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol. Rev. 2007;220:22–34. doi: 10.1111/j.1600-065X.2007.00567.x. [DOI] [PubMed] [Google Scholar]
- 68.Panaretakis T, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009;28:578–590. doi: 10.1038/emboj.2009.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Kepp O, et al. Disruption of the PP1/GADD34 complex induces calreticulin exposure. Cell cycle. 2009;8:3971–3977. doi: 10.4161/cc.8.23.10191. [DOI] [PubMed] [Google Scholar]
- 70.Martins I, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene. 2011;30:1147–1158. doi: 10.1038/onc.2010.500. [DOI] [PubMed] [Google Scholar]
- 71.Pozzi C, et al. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat. Med. 2016;22:624–631. doi: 10.1038/nm.4078. [DOI] [PubMed] [Google Scholar]
- 72.Liu P, et al. Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nat. Commun. 2019;10:1486. doi: 10.1038/s41467-019-09415-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Park, S. J. et al. Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets. mBio10.1128/mBio.01114-20 (2020). [DOI] [PMC free article] [PubMed]
- 74.Chen, G. et al. 3,4-Dimethoxychalcone induces autophagy through activation of the transcription factors TFE3 and TFEB. EMBO Mol. Med.10.15252/emmm.201910469 (2019). [DOI] [PMC free article] [PubMed]
- 75.Rosenfeldt MT, et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature. 2013;504:296–300. doi: 10.1038/nature12865. [DOI] [PubMed] [Google Scholar]
- 76.Vera-Ramirez L, Vodnala SK, Nini R, Hunter KW, Green JE. Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat. Commun. 2018;9:1944. doi: 10.1038/s41467-018-04070-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Radhakrishnan SV, et al. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transpl. 2015;21:30–38. doi: 10.1016/j.bbmt.2014.09.025. [DOI] [PubMed] [Google Scholar]
- 78.Liu P, et al. Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. Oncoimmunology. 2020;9:1789284. doi: 10.1080/2162402X.2020.1789284. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.